Skip to main content

Web Exclusives

Gastrointestinal Cancers

Surufatinib in Combination with Toripalimab Demonstrates Antitumor Responses in Previously Treated Patients with Gastric or Gastroesophageal Adenocarcinoma

Gastrointestinal Cancers

Analysis of PD-L1 Expression by Combined Positive Score May Help Identify Which Patients with Advanced Gastric/Gastroesophageal Junction Cancer Will Respond to Treatment with Nivolumab and Ipilimumab

Gastrointestinal Cancers

Ramucirumab plus Paclitaxel Confers an Overall Survival Advantage Over Placebo in the RAINBOW-Asia Study

Gastrointestinal Cancers

Zolbetuximab in Combination with Epirubicin/Oxaliplatin/Capecitabine Shows Survival Advantage in Patients with Gastric, Gastroesophageal Junction, and Esophageal Cancer: The FAST Study

Gastrointestinal Cancers

Second-Line Nivolumab with Paclitaxel plus Ramucirumab Shows Promising Antitumor Responses in Patients with Advanced Gastric Cancer

Gastrointestinal Cancers

Health-Related Quality-of-Life Scores Higher in Patients with Advanced Gastric Cancer, Esophageal Adenocarcinoma, or Gastroesophageal Junction Cancer Receiving Nivolumab plus Chemotherapy

Gastrointestinal Cancers

First-Line Pembrolizumab plus Chemotherapy Improves Overall Survival and Progression-Free Survival in Patients with Advanced Esophageal Cancer

Gastrointestinal Cancers

Sintilimab Therapy in Patients with Previously Treated Advanced or Metastatic Gastric Cancer Demonstrates Modest Response

Gastrointestinal Cancers

Bavituximab Pembrolizumab Combination Demonstrates Antitumor Activity in Patients with Pretreated Advanced Gastric or Gastroesophageal Junction Cancer

Gastrointestinal Cancers

First-Line Toripalimab Combined with Chemotherapy Conveys Significant Benefits in Patients with Esophageal Squamous-Cell Carcinoma

Page 4 of 43
Results 31 - 40 of 430